MetLife Investment Advisors LLC decreased its holdings in shares of Allakos Inc (NASDAQ:ALLK) by 58.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,042 shares of the company’s stock after selling 5,601 shares during the period. MetLife Investment Advisors LLC’s holdings in Allakos were worth $211,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Legal & General Group Plc bought a new stake in Allakos during the third quarter valued at $56,000. Great West Life Assurance Co. Can purchased a new stake in Allakos during the fourth quarter valued at about $89,000. Bank of America Corp DE raised its position in Allakos by 264.0% during the fourth quarter. Bank of America Corp DE now owns 4,153 shares of the company’s stock valued at $217,000 after purchasing an additional 3,012 shares in the last quarter. Virtus ETF Advisers LLC purchased a new stake in Allakos during the fourth quarter valued at about $262,000. Finally, Rhumbline Advisers purchased a new stake in Allakos during the third quarter valued at about $285,000. 40.31% of the stock is owned by institutional investors.
In other Allakos news, Director John P. Mckearn sold 89,317 shares of the firm’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $36.57, for a total transaction of $3,266,322.69. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Venture Fund (Ohi Rivervest II sold 52,837 shares of the firm’s stock in a transaction dated Thursday, January 24th. The shares were sold at an average price of $42.63, for a total value of $2,252,441.31. The disclosure for this sale can be found here. Insiders have sold 284,373 shares of company stock worth $10,423,897 in the last 90 days.
NASDAQ ALLK opened at $37.65 on Friday. Allakos Inc has a twelve month low of $26.00 and a twelve month high of $65.48.
Separately, Zacks Investment Research upgraded Allakos from a “sell” rating to a “hold” rating in a research report on Tuesday, December 25th.
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Recommended Story: Why is Cost of Capital Important?
Want to see what other hedge funds are holding ALLK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allakos Inc (NASDAQ:ALLK).
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.